Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the research and development of anti-tumor drugs and related products in China. The company offers paclitaxel polymer micelles for injection for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, and gynecological tumors. Shanghai Yizhong Pharmaceutical Co., Ltd. was founded in 2009 and is headquartered in Shanghai, China.
Frequently asked questions
What sector does Shanghai Yizhong Pharmaceutical Co Ltd (688091) operate in?
Shanghai Yizhong Pharmaceutical Co Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Shanghai Yizhong Pharmaceutical Co Ltd (688091) current stock price?
As of the latest data, Shanghai Yizhong Pharmaceutical Co Ltd stock price is CN¥34.70, with a previous close of CN¥35.39. Shanghai Yizhong Pharmaceutical Co Ltd lost -CN¥0.69 in the last trading session, representing a -1.95% loss.
What is Shanghai Yizhong Pharmaceutical Co Ltd (688091) current market capitalization?
Shanghai Yizhong Pharmaceutical Co Ltd market cap is approximately 7.17 billion.
What is Shanghai Yizhong Pharmaceutical Co Ltd (688091) Earnings Per Share (EPS)?
The trailing EPS is CN¥0.34.
What is Shanghai Yizhong Pharmaceutical Co Ltd (688091) Price-to-Earnings (P/E) ratio?
Shanghai Yizhong Pharmaceutical Co Ltd current P/E ratio is 102.06.
What is Shanghai Yizhong Pharmaceutical Co Ltd (688091) EBITDA?
Shanghai Yizhong Pharmaceutical Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 11.39 million.
Does Shanghai Yizhong Pharmaceutical Co Ltd (688091) pay dividends?
No. Shanghai Yizhong Pharmaceutical Co Ltd does not pay a dividend.
What is Shanghai Yizhong Pharmaceutical Co Ltd (688091) beta (volatility) score?
Shanghai Yizhong Pharmaceutical Co Ltd has a beta of -0.439, indicating lower volatility than the overall market.
